tirzepatide patents United States Patent No. 9,474,780 - Tirzepatidepatent expiry date Tirzepatide Patents Understanding Tirzepatide Patents: A Comprehensive Overview

Mounjaro patent expiration The landscape of pharmaceutical innovation is often defined by intellectual property, with patents playing a crucial role in protecting groundbreaking discoveries and ensuring market exclusivity.( 12 ) United States Patent - Googleapis.com For tirzepatide, a revolutionary dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, understanding its tirzepatide patents is essential to grasping its commercial journey and future accessibility. This article delves into the intricate world of tirzepatide's patent protection, exploring its genesis, key advancements, and the implications for its availability.

The genesis of tirzepatide's intellectual property can be traced back to early filings by Eli Lilly and Company. In fact, the synthesis of tirzepatide was first disclosed in patents filed by Eli Lilly and Company as early as 2016Patent Term Extension Application for MOUNJARO® .... These foundational patents established claims over the molecule itself and its method of productionThe present invention is a pharmaceutical GIP/GLP1 co-agonist peptide composition for subcutaneous injection. The composition comprisestirzepatide, NaCl, and .... For instance, United States Patent No. 9,474,780 is a cornerstone, describing a method for the preparation of tirzepatide. This initial disclosure set the stage for a robust portfolio of intellectual property designed to safeguard this innovative therapeutic.

Tirzepatide's patent portfolio is multifaceted, encompassing various aspects of its development and application.2019年6月14日—No. 8,734,394 . The compositions of the present invention have concen- 45 A composition comprisingtirzepatide, NaCl , and dibasic trations ... Beyond the initial composition of matter patents, which protect the chemical structure itself and are generally set to expire around 2036, there are numerous other patentsThe patent for the formulation of tirzepatide (publication number CN112312926A)provides the injection of tirzepatide, filed on June 14, 2019, .... These include formulation patents, which detail stable pharmaceutical compositions, such as those described in US11918623B2 and EP 4656183 A1Tirzepatide | New Drug Approvals. These patents focus on creating stable liquid pharmaceutical compositions that can be administered effectively, often on a once-weekly basissome info on the legal status of compounded tirzepatide. For example, one patent specifically addresses "Stable pharmaceutical compositions comprising tirzepatide," highlighting advancements in drug delivery and patient convenience.US20250019410A1 - Process for the preparation of tirzepatide or ...

Furthermore, the process for the preparation of tirzepatide has been a significant area of patent activity. Multiple patents, including US20250019410A1 and EP4436991A1, detail improved processes for its manufacture. These innovations are crucial for efficient and scalable production, aiming to ensure a consistent supply of the drugProcess for preparing a gip/glp1 dual agonist. The pursuit of an improved process for the preparation of Tirzepatide is a testament to the ongoing efforts to refine manufacturing techniques. Additionally, Eli Lilly has also patented "GIP/GLP1 agonist compositions," further solidifying their intellectual property around this class of drugs.

The broader impact of tirzepatide patents extends to its market availability and the potential for generic competitionPatents Listed in the FDA Orange Book Drug Databaseof Tirzepatide with information and expiry/expiration dates.. The existence of a significant patent thicket surrounding drugs like tirzepatide, often with numerous patent family members across different countries, can influence market dynamics. This complexity is highlighted when considering the intersection of FDA regulations and intellectual property rights, as seen in discussions about compounded tirzepatide. Recent decisions surrounding tirzepatide underscore the interplay between FDA anti-compounding enforcement and private intellectual property rights.EP4436991A1 - Process for the preparation of tirzepatide ...

Understanding the tirzepatide patent expiry date is a key concern for many.The Mounjaro Patent Thicket: Patents expiring in 2036 - GreyB While the core composition of matter patents have a substantial runway, other patents, such as those related to specific formulations or manufacturing processes, may have different expiration timelines. Information regarding patents listed in the FDA Orange Book Drug Database of Tirzepatide with information and expiry/expiration dates serves as a vital resource for tracking these crucial dates. The Mounjaro patent expiration is a frequent topic of discussion, as Mounjaro is a brand-name product that utilizes tirzepatide.

The strategic importance of tirzepatide patents is further emphasized by the fact that tirzepatide products are protected by five-year new chemical entity exclusivity under UGIP/GLP1 agonist compositions - Patent US-11357820-B2.S( 12 ) United States Patent - Googleapis.com. law, in addition to other patent protections. This exclusivity period is distinct from patent terms and offers an additional layer of market protection.

Beyond the United States, tirzepatide patents have been granted in numerous countries. For example, the primary patent on tirzepatide has been granted so far in at least 37 LMICs, including India, showcasing global patent protection efforts. The European Patent Office also plays a role, with applications like EP 4656183 A1 detailing stable pharmaceutical compositions. Analyzing the patent layout in different regions, such as the analysis of the patent layout of Tirzepatide in China, provides insights into global patenting strategies.Eli Lilly just patented a new class of standalone GIP ...

The development of newer therapeutic agents, such as Eli Lilly's new class of standalone GIP receptor agonists, also indicates a continued innovation pipeline protected by intellectual property. While tirzepatide remains a significant molecule, ongoing research and patenting are shaping the future of metabolic and weight management therapies.

In conclusion, tirzepatide patents represent a complex and evolving legal framework essential for protecting the innovation behind this groundbreaking medication2022年5月18日—The synthesis of tirzepatide wasfirst disclosed in patents filed by Eli Lilly and Company. This uses standard solid phase peptide .... From its initial disclosure and improved synthesis methods to stable formulations and global market protections, these patents are a testament to the significant investment in research and development, ultimately shaping the accessibility and future of tirzepatide and similar therapeutic advancements. The list of patents protecting Tirzepatide reflects a comprehensive strategy to secure the drug's market position and encourage continued innovation in the field.